longevity14 min readApr 17, 2026

The Longevity Stack: NAD+ Precursors, Sirtuin Activators, and What the Human Data Actually Shows

Every longevity influencer has "the stack." Here's what the peer-reviewed human trials actually show for NAD+ precursors, sirtuin activators, and the other longevity-coded compounds.

The Longevity Stack Problem

Open any longevity-focused Twitter feed and you''ll find "the stack" — a list of 8 to 20 supplements claimed to slow aging, extend healthspan, or delay age-related disease. The lists vary wildly, the doses are inconsistent, and the evidence behind each component ranges from genuinely impressive to nearly nonexistent.

This post is an honest, compound-by-compound evaluation of the most-mentioned longevity molecules — what the human trial data actually shows, where the evidence is strong, and where it''s still animal-model extrapolation dressed up as clinical recommendation.

How to Evaluate a "Longevity" Compound

Before reviewing individual molecules, it''s worth naming the evidence hierarchy. A compound can have:

  1. Mechanistic plausibility — acts on a pathway known to influence aging biology (mTOR, AMPK, sirtuins, NAD+ pools, senescence)
  2. Animal lifespan data — extends median or maximum lifespan in worms, flies, mice
  3. Human biomarker data — changes surrogate endpoints (epigenetic clocks, NAD+ levels, inflammatory markers)
  4. Human outcome data — trials with morbidity or mortality endpoints

Most "longevity stacks" are built on 1 and 2. Only a handful of compounds have meaningful 3, and almost none have 4. Understanding this hierarchy clarifies what you''re actually buying.

NAD+ Precursors: NMN and NR

The Pitch

NAD+ levels decline with age. Sirtuins and PARP enzymes require NAD+ to function. Supplementing NAD+ precursors should restore cellular function and extend healthspan.

The Mechanism

  • Nicotinamide riboside (NR) — converted to NMN, then to NAD+ intracellularly
  • Nicotinamide mononucleotide (NMN) — one step closer to NAD+, though oral bioavailability is debated

What the Research Actually Shows

Animal data: Consistent. Both NR and NMN raise tissue NAD+ in mice and improve several age-related markers.

Human data:

  • Martens et al. (2018): NR elevated whole-blood NAD+ by ~60% in middle-aged/older adults. Modest blood pressure reduction in subset.
  • Dolopikou et al. (2020) and several follow-ups: NR consistently raises blood NAD+ in humans.
  • Yoshino et al. (2021, Science): NMN improved muscle insulin sensitivity in prediabetic women — one of the first well-controlled NMN RCTs in humans.
  • Yamane et al. (2022) and follow-up NMN trials: Mixed results on performance, metabolic, and cognitive endpoints.

What''s missing: No human lifespan data. No human outcome data. Biomarker elevation is reliable; what that translates to for actual aging remains an open question.

Compare the two: See our NMN vs NAD+ comparison for a deeper look.

Verdict: Legitimate mechanism, reliable biomarker effects, unknown real-world benefit. Among the more defensible longevity supplements on biomarker grounds.

Resveratrol and Other Polyphenols

The Pitch

Resveratrol activates SIRT1, mimicking caloric restriction.

What the Research Actually Shows

  • Animal data: Mixed. Lifespan extension in yeast, worms, and mice on high-fat diet — but not in mice on standard chow. Effects are diet-dependent.
  • Human data: Dozens of trials. Effects on cardiovascular markers, insulin sensitivity, and inflammation are modest and inconsistent. No human lifespan data.
  • Bioavailability problem: Oral resveratrol is poorly absorbed. Most human trials use extracts and find modest effects on biomarkers.

What''s missing: Convincing evidence that resveratrol directly activates SIRT1 at physiologic concentrations in humans. The original mechanism papers have been contested.

Verdict: The original hype has not survived the trial data. Not useless, but the evidence doesn''t justify its prominence in most longevity stacks.

Spermidine

The Pitch

Spermidine induces autophagy — the cellular recycling process that declines with age.

What the Research Actually Shows

  • Animal data: Spermidine extends lifespan in yeast, flies, worms, and mice across multiple studies. Autophagy induction appears causally involved.
  • Observational human data: Eijkelenboom et al. (2018) — higher dietary spermidine intake associated with lower all-cause mortality in a large European cohort.
  • Small clinical trials: Some cognitive and cardiovascular endpoint trials show modest effects.

What''s missing: Large prospective RCTs with hard outcomes.

Verdict: One of the more interesting longevity molecules. Mechanistic story is clean, observational data is suggestive, human trial data is growing. Dietary sources (wheat germ, aged cheese, mushrooms) are a reasonable alternative to supplementation.

Metformin

The Pitch

Long-used diabetes drug; activates AMPK; appeared to reduce cancer and mortality in diabetic cohorts.

What the Research Actually Shows

  • Observational: Diabetics on metformin have lower cancer incidence and overall mortality than matched non-diabetics in several cohort studies.
  • Mechanistic: Activates AMPK, modulates mTOR, affects gut microbiome — all pathways implicated in aging.
  • The TAME trial (Targeting Aging with Metformin) is designed to test metformin for healthspan outcomes in non-diabetics. Results are pending.
  • Countervailing data: Kulkarni et al. (2020) — metformin may blunt exercise-induced muscle and mitochondrial adaptations.

Verdict: Genuine candidate longevity drug with decades of safety data. The non-diabetic benefit is plausible but not yet proven. The exercise-blunting signal is real and worth considering for active populations.

Rapamycin (Sirolimus)

The Pitch

mTOR inhibitor. The most consistent lifespan-extending compound in mice across strains, sexes, and starting ages.

What the Research Actually Shows

  • Animal data: The strongest lifespan-extension data of any compound in mice. Effects replicate across labs, strains, and starting ages.
  • Mechanistic: mTOR inhibition is a central aging pathway; rapamycin is the cleanest pharmacological intervention for it.
  • Human data: Decades of clinical use as an immunosuppressant. Small off-label trials in healthy populations (Mannick et al. 2014, 2018 on immune function in elderly; PEARL trial on general healthspan) have shown modest but real effects on aging-relevant biomarkers.

Caveats:

  • Continuous high-dose rapamycin causes significant side effects (immunosuppression, glucose dysregulation, mucositis).
  • Intermittent low-dose protocols (as used in most healthy-population off-label research) have better tolerability profiles but less outcome data.
  • Prescription-only drug with legitimate research and off-label clinical use — not a supplement.

Verdict: The most scientifically credible "longevity drug" by animal evidence; human outcome data is still emerging. Prescription-managed protocols with a longevity-focused clinician are the defensible research path.

Fisetin (Senolytic)

The Pitch

Clears senescent cells that accumulate with age and drive chronic inflammation.

What the Research Actually Shows

  • Animal data: Fisetin extends healthspan and lifespan in aged mice. Senolytic activity is plausibly causal.
  • Human data: Small clinical trials (typically 2-day "hit and run" protocols) are ongoing. Preliminary signals on senescence biomarkers are encouraging.
  • Commercial quercetin + dasatinib protocols: Dasatinib is a prescription cancer drug; the combination has been used in small senolytic trials with interesting results.

Verdict: One of the more exciting research areas. Protocols are still being defined. Fisetin is generally well-tolerated at research doses.

Omega-3 Fatty Acids

The Pitch

Multiple mechanisms — inflammation reduction, membrane fluidity, cardiovascular markers.

What the Research Actually Shows

  • Extensive human trial data.
  • Cardiovascular: Meta-analyses show modest reduction in cardiac death, particularly with higher EPA/DHA doses.
  • Cognitive: Mixed but generally positive for cognitive decline in older adults.
  • Telomere length: Some trials show omega-3 supplementation slows telomere attrition.
  • All-cause mortality: A few trials show small effects.

Verdict: The boring answer with some of the best human outcome data. Arguably more evidence-backed than the exotic longevity compounds combined. See our omega-3 research profile.

Vitamin D

The Pitch

Deficiency is common; associated with mortality, cancer, metabolic, and immune outcomes.

What the Research Actually Shows

  • Observational: Strong associations between low vitamin D and adverse outcomes.
  • RCT data: Mixed. Correcting frank deficiency helps bone health and some outcomes. Supplementing already-replete individuals shows little benefit.
  • VITAL trial (2019): No reduction in cancer or cardiovascular events overall, but signals in subgroups.

Verdict: Worth measuring; worth correcting if low. Supplementing without knowing baseline is suboptimal.

What I''m Leaving Off

Several commonly-recommended compounds have insufficient evidence to justify the stack real estate:

  • PQQ: Interesting mechanism; trial data is weak.
  • C60 / fullerenes: Extraordinary claims, no human evidence.
  • TMG (trimethylglycine): Often bundled with NMN/NR; the methyl-donor argument is mechanistically plausible but the trial data for added benefit is limited.
  • Various "senolytic blends": Most commercial products don''t match the doses used in research.
  • Exosome/stem-cell products: Unregulated, evidence-poor for most indications.

A Research-Informed Minimalist Stack

If you''re building a defensible longevity research stack based on human trial data:

Strong evidence tier:

Defensible-biomarker tier:

  • NMN or NR — reliable NAD+ elevation
  • Spermidine — autophagy, observational mortality data

Clinical supervision tier:

  • Metformin — off-label, with lab monitoring
  • Rapamycin — off-label, with longevity-clinician supervision

Monitoring

Any longevity research protocol is worth monitoring with:

Where It Fits in Research Protocols

Longevity research overlaps with:

The Bottom Line

The longevity supplement space runs on mechanistic stories, animal data, and aspirational framing. Genuine human outcome data is concentrated in a smaller set of boring compounds (omega-3, vitamin D, creatine) plus a few pharmaceutical candidates under legitimate off-label longevity research (metformin, rapamycin).

NAD+ precursors, spermidine, and fisetin are the most-defensible of the specifically-longevity-coded supplements. Resveratrol and most "senolytic blends" haven''t earned their stack placement.

A research-informed minimalist approach beats a 15-supplement maximalist stack almost every time — both for evidence-alignment and for the ability to actually measure individual response.

For research and educational purposes only. Not medical advice. Always consult a qualified healthcare provider.

Want a personalized protocol?

Take the assessment and we'll match you to the right research stack based on your goals.

Start your assessment →
Research disclaimer. All content is for informational and educational purposes only. Products and compounds discussed are for research purposes only. This is not medical advice. Always consult a qualified healthcare provider.